Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Read More: ...

The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

This affirmation follows the recent release of positive Phase 3 data on Vertex's pain management drug, VX-548 (suzetrigine), which is being developed as a non-opioid alternative for treating acute ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...